^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    JAK1 S703I

    i
    Other names: Janus Kinase 1, Tyrosine-Protein Kinase JAK1, JAK1B, JAK1A, JAK-1, JTK3
    Entrez ID:
    3716
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    over4years
    [VIRTUAL] The genomic characteristics of JAK family in 11159 Chinese solid tumour patients (ESMO 2020)
    Background Constitute activation of JAK signaling pathway is associated with the pathogenesis of multiple hematological tumors such as myelofibrosis, which can be targeted by JAK inhibitors, Ruxolitinib and Fedratinib. Legal entity responsible for the study: The authors. Funding: Has not received any funding.
    Clinical
    |
    JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1) • JAK3 (Janus Kinase 3)
    |
    JAK2 V617F • JAK3 mutation • JAK1 S703I
    |
    Jakafi (ruxolitinib) • Inrebic (fedratinib)